Welcome to our dedicated page for OMADA HEALTH news (Ticker: OMDA), a resource for investors and traders seeking the latest updates and insights on OMADA HEALTH stock.
Omada Health, Inc. (Nasdaq: OMDA) is a virtual-first, between-visit healthcare provider focused on cardiometabolic conditions such as diabetes, hypertension, prediabetes, and obesity, as well as musculoskeletal issues. The OMDA news page on Stock Titan aggregates company announcements, clinical updates, product news, and financial disclosures so readers can follow how Omada’s virtual care platform and GLP-1 programs evolve over time.
News about Omada Health frequently covers quarterly and annual financial results, including revenue trends, member growth, and updates shared through earnings press releases and related Form 8-K filings. Investors can also see announcements about Omada’s participation in major healthcare and investor conferences, where senior management presents the company’s strategy and performance.
Because Omada operates in digital chronic care and GLP-1 support, its news flow also includes clinical and real-world evidence analyses from Omada’s GLP-1 Care Tracks and Enhanced GLP-1 Care Track, along with updates from the Omada Insights Lab ANSWERS Initiative. These releases describe findings on medication persistence, weight outcomes, and weight maintenance after GLP-1 discontinuation for members enrolled in Omada programs.
Product and platform updates are another recurring theme, such as the launch of Meal Map, an AI-powered nutrition experience focused on nutrient quality, and announcements about OmadaSpark, the company’s AI-powered nutrition education tool. Omada also issues news about its prescribing and medication management capability for anti-obesity medications, including GLP-1s, and about enhancements to its AI-enabled support tools.
By reviewing the OMDA news feed, readers can track how Omada’s member base, customer relationships, GLP-1-related offerings, and AI-powered capabilities are described in official communications, and how the company positions its role in chronic care and virtual healthcare delivery.
Omada Health (OMDA) released an independent Markov microsimulation model estimating up to $11,142 in five‑year gross medical cost savings per GLP‑1 member.
The GlobalData analysis used nationally representative datasets plus clinical data from nearly 25,000 Omada GLP‑1 Care Track members to project disease onset and healthcare costs. Members persisting on GLP‑1 therapy for at least 12 months were estimated to save about 30% more at year five than those persisting at least six months ($11,142 vs. $8,578). More engaged members, defined as 9.5+ actions per week, were estimated to save an additional $1,891 at five years. New‑onset type 2 diabetes and hypertension were projected to decline 49% and 28% at five years, with five‑year cumulative savings of $8,578 for the six‑month persistence cohort versus standard care and differentiated savings across age and racial/ethnic groups.
Omada Health (Nasdaq: OMDA) reported Q2 2026 revenue of $88 million, up 43% from $61 million in Q2 2025, with total members increasing 45% year over year. GAAP gross margin reached a quarterly record of 73% (non‑GAAP 74%), and Omada generated net income of $5 million versus a $5 million loss a year ago. Adjusted EBITDA was $11 million, compared with a $0.2 million loss in Q2 2025, and cash and equivalents were $222 million.
Operationally, Omada expanded its HCSC partnership to an additional 1.5 million covered lives, launched its first cholesterol management deployment in July, and signed the first customer for its prescribing program, with revenue expected in 2027. The company raised its 2026 outlook to $334–$340 million in revenue and $21–$27 million in adjusted EBITDA. Omada also announced that Sean Duffy will become Founder and Executive Chair and Wei‑Li Shao CEO effective January 1, 2027.
Omada Health (Nasdaq: OMDA) will release its second quarter 2026 financial results on Thursday, August 6, 2026, after market close. Management will host a conference call at 4:30 p.m. ET the same day, with a live audio webcast and replay available on the company’s investor relations website.
Omada Health (Nasdaq: OMDA) will release its 2026 quarterly financial results on Thursday, August 6, 2026, after market close, and hold a conference call at 4:30 p.m. ET to review the results.
A live audio webcast and a replay (available for about 12 months) will be accessible via the Omada Health investor relations website, with optional pre-registration for the conference call through an online link.
Omada Health (Nasdaq: OMDA) announced it will host its first Investor Day on Thursday, September 10, 2026, beginning at 1:00 pm EDT in New York City. The half-day, in-person event will feature senior management discussing Omada’s vision, strategy, and long-term growth plans, with live webcast access and replay available via the company’s investor relations website.
Omada Health (Nasdaq: OMDA) announced that senior management will participate in Canaccord Genuity’s 46th Annual Growth Conference in Boston. The appearance includes a fireside chat on Tuesday, August 11, at 8:00 a.m. EDT, with a live webcast and replay available at Omada Health’s investor relations events webpage.
Omada Health (NASDAQ: OMDA) joined the Digital Medicine Society (DiMe) as title sponsor of the Post-Contracting Operational Readiness for Virtual-First Care project. The 3.5‑month initiative will build a toolkit that helps payers and virtual-first providers integrate, list, and reimburse contracted virtual care within 90 days.
Omada Health (Nasdaq: OMDA) announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 in Miami. The appearance includes a fireside chat on Wednesday, June 10, at 8:20 a.m. PST, with a live webcast and replay available online.
Omada Health (Nasdaq: OMDA) will join Eli Lilly’s Employer Connect as an independent program administrator to offer its GLP-1 Care Track to employers, adding a direct-to-employer channel alongside PBM and cash-pay pathways.
The integration provides transparent net cost for Zepbound, defined employer contribution levels, and options to pair medications with ongoing lifestyle support. Omada cites a survey of >3,000 GLP-1 patients showing coverage gaps, rising out-of-pocket costs, and high demand for nutrition and exercise support while on therapy.
Omada Health (Nasdaq: OMDA) reported Q1 2026 results for the quarter ended March 31, 2026. Total Members reached 1.02 million (up 51% YoY). Revenue was $78.0 million (up 42% YoY). Gross margin was 62% (non-GAAP 64%). Net loss narrowed to $3.0 million; adjusted EBITDA was $1.0 million. Cash and cash equivalents were $212 million. Omada added Optum Rx collaboration and now has relationships with the nation’s three leading PBMs. 2026 guidance: revenue $322–$330 million (midpoint +25% vs 2025); adjusted EBITDA $14–$20 million (midpoint ~3x 2025).